title: The cost effectiveness of in vivo dosimetry is not proven.
abstract: In vivo dosimetry is a check of the radiotherapy treatment process. Recently, it has been argued that in vivo dosimetry at the start of every patient's radiotherapy is cost effective. We have examined and extended the cost effectiveness argument and show that the model does not deliver the stated benefits.
authors.affiliation: North Western Medical Physics, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. ranald.mackay@physics.cr.man.ac.uk
authors.forename: R I
authors.initials: RI
authors.lastname: MacKay
authors.forename: P C
authors.initials: PC
authors.lastname: Williams
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000191:economics* / Q000401:mortality; D009369:Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011785:Quality Assurance, Health Care; D011829:Radiation Dosage; D011874:Radiometry / Q000191:economics*